Latest Breaking News On - Pieris australia pty ltd - Page 1 : comparemela.com

The interleukin-4 receptor (IL-4R) is emerging as a potential drug target, projected to potentially be worth up to 10 billion USD. In this article, ACROBiosystems discusses why it is such an attractive drug target and what this could entail.

Alex smithKeymed biosciencesSanofi regeneronAtridia pty ltdSyneos healthPieris australia pty ltdAkeso pharmaceuticalsJiangsu hengrui pharmaceuticalsSponsored contentAtopic dermatitisNasal polypsNasal disordersPty ltdNovamab biopharmaceuticalsImage creditHis tag